Imago BioSciences Revenue and Competitors
Estimated Revenue & Valuation
- Imago BioSciences's estimated annual revenue is currently $5.3M per year.
- Imago BioSciences's estimated revenue per employee is $135,128
- Imago BioSciences's current valuation is $619.6M. (January 2022)
- Imago BioSciences has 39 Employees.
- Imago BioSciences grew their employee count by 44% last year.
Imago BioSciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Imago BioSciences?
Our scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow. Our clinical focus is on acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia. These diseases share several features. They are diseases caused by acquired mutations in blood stem cells. To varying degrees, these mutations drive excessive growth of bone marrow cells, as well as alter their function. For example, myelofibrosis can be viewed as a chronic inflammatory disorder in which inflammatory cytokines and growth factors cause bone marrow cells to alter the architecture of and ultimately destroy the bone marrow. Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Our first clinical inhibitor of LSD1, bomedemstat (or IMG-7289) is being studied in patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms including myelofibrosis. Future clinical studies are planned for other related diseases.keywords:N/A
Number of Employees
Employee Growth %
Imago BioSciences News
Zero analysts have made estimates for Imago BioSciences' earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate...
On average, analysts expect that Imago BioSciences will report full year earnings of ($1.76) per share for the current fiscal year, with EPS...
Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Imago BioSciences Executives
|Wan-Jen Hong||Chief Medical Officer|
|Michael Arenberg||Chief Operating and Business Officer|
|Michael Arenberg||Chief Operating Officer and Chief Business Officer|
|Laura Eichorn||Chief Operating Officer, Interim Chief Financial Officer|
|Matthew Plunkett||Chief Financial Officer|
|Jennifer Peppe||Senior Vice President, Clinical Operations|
|Amy Tapper||Senior Vice President, Non-Clinical and CMC|
|Ruth Paul||Vice President Regulatory Affairs|